First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

• Status: Recruiting
• Trial end date: 2024-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to see what effects the treatment regimen chemotherapy (carboplatin and paclitaxel) plus immunotherapy (pembrolizumab), has on patients who have been diagnosed with head/neck squamous cell carcinoma and are unable to take the drug 5-fluorouracil

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Collaborator: National Cancer Institute (NCI)
• Treatments: Carboplatin; Paclitaxel; Pembrolizumab

Criteria

Inclusion Criteria:

• Recurrent or metastatic squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx that is incurable by local therapies (i.e. radiation or surgery) and either locoregionally advanced or with at least one distant metastasis.

• Histologic or cytologic confirmation of malignancy by pathology report.

• Not a candidate for infusional 5FU (mucositis, 5-day infusional pump not feasible, patient refusal, other).

• 18 years old or greater.

• ECOG performance status of 0-2.

• Life expectancy of greater than 3 months.

• Patients must have normal organ and marrow function as defined: Absolute neutrophil count >1,000/mcL, platelets >75,000/mcL, total bilirubin ≤2 mg/dL

• Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).

Exclusion Criteria:

• No prior systemic cancer-directed therapy administered in the recurrent or metastatic setting. Prior treatments are allowed if they were administered with curative intent prior to incurable progression of disease. Prior treatments for other cancers are also allowed.

• Untreated, symptomatic central nervous system (CNS) metastases.

• Active autoimmune disease requiring systemic immunosuppression.

• History of autoimmune pneumonitis requiring high-dose systemic steroids (equivalent prednisone >20 mg/day for >1week).

• History of grade ≥3 hypersensitivity reaction to carboplatin or paclitaxel.

• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Pregnant women are excluded from this study because paclitaxel and carboplatin are Class D agents with significant potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these drugs, breastfeeding should be discontinued during the study.